Firstly, and strongly supported by the present findings, INSL3 is known to promote bone metabolism, with genetic defects in the receptor RXFP2 in mice and humans both leading to osteoporosis and osteopenia (24), and with clear effects on bone cells in culture (25). This evidence concerns the gene INSL3 and Osteopenia.